Natera, Inc. (NASDAQ:NTRA) Insider Daniel Rabinowitz Sells 787 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Daniel Rabinowitz sold 787 shares of Natera stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total value of $71,916.06. Following the transaction, the insider now owns 205,552 shares of the company’s stock, valued at $18,783,341.76. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The stock was sold at an average price of $89.01, for a total value of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63.

Natera Price Performance

Natera stock opened at $91.04 on Wednesday. The stock has a fifty day moving average of $86.40 and a 200-day moving average of $66.49. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The stock has a market capitalization of $10.99 billion, a P/E ratio of -24.02 and a beta of 1.37.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. On average, sell-side analysts expect that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NTRA shares. Canaccord Genuity Group lifted their price target on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and lifted their price target for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. Stephens reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 15th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $86.40.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently modified their holdings of NTRA. National Bank of Canada FI purchased a new stake in shares of Natera in the third quarter worth approximately $1,932,000. CWM LLC raised its stake in shares of Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock worth $58,000 after purchasing an additional 911 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Natera by 1,503.2% in the third quarter. SG Americas Securities LLC now owns 97,973 shares of the medical research company’s stock worth $4,335,000 after purchasing an additional 91,862 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of Natera in the third quarter worth approximately $364,000. Finally, Xponance Inc. raised its stake in shares of Natera by 1.8% in the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after purchasing an additional 261 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.